$BGLC News

BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence

BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

BioNexus Gene Lab Appoints Matthew Barsing As Chairman

BioNexus Gene Lab Appoints Matthew Barsing As Chairman

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market

BioNexus Gene Lab Commences Its 2026 Deployment Phase For VitaGuard Minimal Residual Disease Platform

BioNexus Gene Lab Names Matthew L. Barsing As Chairman Of The Board

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

BioNexus Gene Lab Corp Secures$500M Equity Facility From ARC Group

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene

BioNexus Gene Lab Executes Intellectual Property License Agreement For Southeast Asia With Fidelion Diagnostics For VitaGuard Minimal Residual Disease Liquid Biopsy Platform

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization

BioNexus Enters Into Definitive Agreements With Fidelion And Tongshu To Commercialize VitaGuard, Tumor-Naïve Liquid-Biopsy Platform For Minimal Residual Disease

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

BioNexus Gene Lab Files $100M Shelf Registration And Establishes $20M ATM Program To Support Growth In Precision Oncology And Gene-Based Technologies

BioNexus Gene Lab Files For Mixed Shelf Of Up To $100M